INTRODUCTION: Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors, which are mostly benign in nature. Amongst all genes, Succinate Dehydrogenase Subunit D (SDHD) is the most commonly mutated in familial HNPGLs. In about 30% of HNPGLs, germline mutations in SDHD can also occur in the absence of positive family history, thus giving rise to "occult familial" cases. Our aim was to evaluate the pattern of SDHD germline mutations in Czech patients with HNPGLs. MATERIALS AND METHODS: We analyzed a total of 105 patients with HNPGLs from the Otorhinolaryngology departments of 2 tertiary centers between 2006 - 2021. All underwent complex diagnostic work-up and were also consented for genetic analysis. RESULTS: Eighty patients aged 13-76 years were included; around 60% with multiple PGLs were males. Carotid body tumor was the most frequently diagnosed tumor. Germline SDHD mutation was found in only 12% of the Czech patients; approximately 78% of those harboring the mutation had negative family history. The mutation traits had higher affiliation for multiple tumors with nearly 70% patients of ≤ 40 years of age. CONCLUSION: An SDHD mutation variant was shared amongst unrelated patients but no founder-effect was established. Our findings confirmed that the pattern of SDHD mutation distribution amongst HNPGLs in Czech Republic differs from most studies worldwide.

3rd Department of Medicine Department of Endocrinology and Metabolsim of the 1st Faculty of Medicine and General University Hospital Prague Prague Czechia

Department of Otorhinolaryngology and Head and Neck Surgery Charles University 1st Faculty of Medicine and University Hospital Motol Prague Czechia

Department of Otorhinolaryngology Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady Prague Czechia

Department of Pediatric Hematology and Oncology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czechia

Institute of Biology and Medical Genetics of the 1st Faculty of Medicine and General University Hospital Prague Prague Czechia

Section of Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda MD United States

See more in PubMed

Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol (2022) 33(1):90–114. doi: 10.1007/s12022-022-09704-6 PubMed DOI

Mete O, Wenig BM. Update from the 5th edition of the World Health Organization Classification of head and neck tumors: overview of the 2022 WHO classification of head and neck neuroendocrine neoplasms. Head Neck Pathol (2022) 16(1):123–42. doi: 10.1007/s12105-022-01435-8 PubMed DOI PMC

Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR, et al. . Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 35(5):795–819. doi: 10.1210/er.2014-1026 PubMed DOI PMC

Sandow L, Thawani R, Kim MS, Heinrich MC. Paraganglioma of the head and neck: A review. Endocrine Practice (2023) 29(2):141–7. doi: 10.1016/j.eprac.2022.10.002 PubMed DOI PMC

Boedeker CC. Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg (2011) 10:Doc03. doi: 10.3205/cto000076 PubMed DOI PMC

Guha A, Musil Z, Vicha A, Zelinka T, Pacak K, Astl J, et al. . A systematic review on the genetic analysis of paragangliomas: Primarily focused on head and neck paragangliomas. Neoplasma (2019) 66:671–80. doi: 10.4149/neo_2018_181208N933 PubMed DOI PMC

Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. . Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab (2001) 86(11):5210–6. doi: 10.1210/jcem.86.11.8034 PubMed DOI

Robertson V, Poli F, Hobson B, Saratzis A, Ross Naylor A. A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours. Eur J Vasc Endovascular Surgery (2019) 57(4):477–86. doi: 10.1016/j.ejvs.2018.10.038 PubMed DOI

Smith JD, Harvey RN, Darr OA, Prince ME, Bradford CR, Wolf GT, et al. . Head and neck paragangliomas: A two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol (2017) 2(6):380–9. doi: 10.1002/lio2.122 PubMed DOI PMC

Biller HF, Som P, Lawson W, Rosenfeld R. Glomus vagale tumors. Ann Otol Rhinol Laryngol (1989) 98(1):21–6. doi: 10.1177/000348948909800105 PubMed DOI

Taïeb D, Wanna GB, Ahmad M, Lussey-Lepoutre C, Perrier ND, Nölting S, et al. . Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes Endocrinol (2023) 11(5):345–61. doi: 10.1016/S2213-8587(23)00038-4 PubMed DOI PMC

Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (1979) 287(5454):848–51. doi: 10.1126/science.287.5454.848 PubMed DOI

Gimenez-Roqueplo A-P, Dahia P, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Hormone Metab Res (2012) 44(5):328–33. doi: 10.1055/s-0031-1301302 PubMed DOI

Dannenberg H, Dinjens WNM, Abbou M, Van Urk H, Pauw BKH, Mouwen D, et al. . Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin Cancer Res (2002) 8(7):2061–6. PubMed

Lima J, Feijão T, Ferreira da Silva A, Pereira-Castro I, Fernandez-Ballester G, Máximo V, et al. . High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in Northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab (2007) 92(12):4853–64. doi: 10.1210/jc.2007-0640 PubMed DOI

Heesterman BL, Bayley JP, Tops CM, Hes FJ, van Brussel BTJ, Corssmit EPM, et al. . High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet (2013) 21(4):469–70. doi: 10.1038/ejhg.2012.203 PubMed DOI PMC

Richter S, Qiu B, Ghering M, Kunath C, Constantinescu G, Luths C, et al. . Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocr Relat Cancer (2022) 29(4):213–24. doi: 10.1530/ERC-21-0359 PubMed DOI PMC

Guha A, Vicha A, Zelinka T, Musil Z, Chovanec M. Genetic variants in patients with multiple head and neck paragangliomas: dilemma in management. Biomedicines (2021) 9(6):626. doi: 10.3390/biomedicines9060626 PubMed DOI PMC

Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, et al. . The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab (2009) 94(8):2817–27. doi: 10.1210/jc.2008-2504 PubMed DOI

Neumann HPH, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. . Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 69(8):3650–6. doi: 10.1158/0008-5472.CAN-08-4057 PubMed DOI

Astuti D, Hart-Holden N, Latif F, Lalloo F, Black GC, Lim C, et al. . Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) (2003) 59(6):728–33. doi: 10.1046/j.1365-2265.2003.01914.x PubMed DOI

Badenhop RF. The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. J Med Genet (2004) 41(7):e99–9. doi: 10.1136/jmg.2003.011551 PubMed DOI PMC

Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, et al. . Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet (2002) 39(3):178–83. doi: 10.1136/jmg.39.3.178 PubMed DOI PMC

Benn DE, Gimenez-Roqueplo A-P, Reilly JR, Bertherat J, Burgess J, Byth K, et al. . Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2006) 91(3):827–36. doi: 10.1210/jc.2005-1862 PubMed DOI

Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A, Zanaret M. Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Oto-Rhino-Laryngol (2008) 265(5):557–63. doi: 10.1007/s00405-007-0517-4 PubMed DOI

Hensen EF, Siemers MD, Jansen JC, Corssmit EPM, Romijn JA, Tops CMJ, et al. . Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin Endocrinol (Oxf) (2011) 75(5):650–5. doi: 10.1111/j.1365-2265.2011.04097.x PubMed DOI

Neumann HPH, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al. . Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 292(8):943–51. doi: 10.1001/jama.292.8.943 PubMed DOI

Pandit R, Khadilkar K, Sarathi V, Kasaliwal R, Goroshi M, Khare S, et al. . Germline mutations and genotype–phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. Eur J Endocrinol (2016) 175(4):311–23. doi: 10.1530/EJE-16-0126 PubMed DOI

Papaspyrou K, Mewes T, Rossmann H, Fottner C, Schneider-Raetzke B, Bartsch O, et al. . Head and neck paragangliomas: Report of 175 patients (1989-2010). Head Neck (2012) 34(5):632–7. doi: 10.1002/hed.21790 PubMed DOI

Persu A, Hamoir M, Grégoire V, Garin P, Duvivier E, Reychler H, et al. . High prevalence of SDHB mutations in head and neck paraganglioma in Belgium. J Hypertens (2008) 26(7):1395–401. doi: 10.1097/HJH.0b013e3282ffdc54 PubMed DOI

Piccini V, Rapizzi E, Bacca A, Di Trapani G, Pulli R, Giachè V, et al. . Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer (2012) 19(2):149–55. doi: 10.1530/ERC-11-0369 PubMed DOI

Snezhkina AV, Fedorova MS, Pavlov VS, Kalinin DV, Golovyuk AL, Pudova EA, et al. . Mutation frequency in main susceptibility genes among patients with head and neck paragangliomas. Front Genet (2020) 18:614908. doi: 10.3389/fgene.2020.614908 PubMed DOI PMC

Taschner PEM, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Bröcker-Vriends AHJT, et al. . Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHD gene. Genes Chromosomes Cancer (2001) 31(3):274–81. doi: 10.1002/gcc.1144 PubMed DOI

Vosecka T, Vicha A, Zelinka T, Jencova P, Pacak K, Duskova J, et al. . Absence of BRAF mutation in pheochromocytoma and paraganglioma. Neoplasma (2017) 64(2):278–82. doi: 10.4149/neo_2017_215 PubMed DOI PMC

Gómez AM, Soares DC, Costa AAB, Pereira DP, Achatz MI, Formiga MN. Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance. Arch Endocrinol Metab (2019) 11:369–75. doi: 10.20945/2359-3997000000145 PubMed DOI PMC

Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, et al. . The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab (2012) 97(4):E637–41. doi: 10.1210/jc.2011-2597 PubMed DOI

van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. . An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 10(8):764–71. doi: 10.1016/S1470-2045(09)70164-0 PubMed DOI PMC

Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, et al. . Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer (2014) 21(4):567–77. doi: 10.1530/ERC-14-0254 PubMed DOI PMC

Sen I, Young WF, Kasperbauer JL, Polonis K, Harmsen WS, Colglazier JJ, et al. . Tumor-specific prognosis of mutation-positive patients with head and neck paragangliomas. J Vasc Surg (2020) 71(5):1602–1612.e2. doi: 10.1016/j.jvs.2019.08.232 PubMed DOI

Fliedner SMJ, Lehnert H, Pacak K. Metastatic paraganglioma. Semin Oncol (2010) 37(6):627–37. doi: 10.1053/j.seminoncol.2010.10.017 PubMed DOI PMC

Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo A-P, Grossman AB, et al. . Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab (2007) 3(2):92–102. doi: 10.1038/ncpendmet0396 PubMed DOI

Paragangliomas and syringomyelia in Tetralogy of Fallot-A case report and literature review